Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination [Erratum]

Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Vázquez-Álvarez AO, Bautista-Castro MA, Rodríguez-Herrera LY. *Clin Ophthalmol.* 2021;15:583–590.

On page 587, **Table 3** was distorted during the correction stage and published in error. The correct **Table 3** should read as follows.

This error was introduced by the typesetting team during the editing process and was not picked up before publication.

Table 3 ADRs of TBD vs Reported by Individual Active Ingredient

SOC	PT	TBD	B	p	T	p	D	p
Eye disorders	Eye irritation	30.9%	9%	<0.0001 ^{c***a}	12%	<0.0001 ^{c***a}	32%	0.7709 ^c
	Eye pruritus	1.2%	20%	<0.0001 ^{d***b}	5%	0.0183 ^{d**b}	1%	>0.9999 ^d
	Vision blurred	2%	4%	0.1898 ^c	5%	0.0840 ^c	5%	0.0840 ^c
	Ocular hyperemia	0.4%	20%	<0.0001 ^{d***b}	5%	0.0020 ^{d***b}	5%	0.0020 ^{d***b}
	Eye pain	0.4%	4%	0.0061 ^{d***b}	5%	0.0020 ^{d***b}	-	-
Gastrointestinal disorders	Dry mouth	0.4%	9%	<0.0001 ^{d***b}	5%	0.0020 ^{d***b}	-	-
Nervous system disorders	Dysgeusia	0.8%	4%	0.0194 ^{d**b}	-	-	25%	<0.0001 ^{d***b}
	Headache	0.4%	4%	0.0061 ^{d***b}	5%	0.0020 ^{d***b}	-	-
	Somnolence	0.4%	4%	0.0061 ^{d***b}	-	-	5%	0.0020 ^{d***b}
Investigations	Blood pressure decreased	0.4%	4%	0.0061 ^{d***b}	1%	0.3153 ^d	-	-
Infections and infestations	Nasopharyngitis	0.8%	-	-	-	-	-	-

Notes: Significance, *p<0.05, **p<0.01, ***p<0.001. ^aThe statistical significance is above expected to TBD. ^bThe statistical significance is below expected to TBD. ^cPearson Chi-square test. ^dFisher's exact test.

Abbreviations: SOC, System Organ Class; PT, preferred term; TBD, timolol/brimonidine/dorzolamide fixed combination; T, timolol; B, brimonidine; D, dorzolamide.